VasoDynamics strengthens financial management with key appointment to enable progress to market access
3rd September 2024 – VasoDynamics Ltd, the pharmaceutical company developing preventive therapies for common complications in cancer treatment, today announces a key CFO appointment to strengthen the team.
Ningfeng Fiona Li, CEO of VasoDynamics, said:
“With the rapid progression of our company’s pipeline programmes and fundraise campaign, I am delighted to announce the appointment of Mr Peter McGowan as Chief Financial Officer who brings extensive and valuable experience in this area as we move the company forward.”
Mr Peter McGowan, Chief Financial Officer
Peter McGowan brings 30 years of international experience in both public and private companies including as CFO of several emerging biotechnology companies, helping them grow and optimise their performance. Peter specialises in ensuring effective finance and administrative functions, raising venture capital and supporting business development. He previously held senior global finance leadership positions at Mundipharma and PPD, a global clinical contract research organisation. Peter is a Fellow of the Association of Chartered Certified Accountants.
Mr McGowan said “I am delighted to have joined VasoDynamics at such an exciting time of the company’s development, with several programmes entering late-stage clinical development phases. I am looking forward to working with the Board and the executive team as we accelerate the company’s clinical trial programmes progress and potential commercial opportunities.”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk
Gary Bower, COO
gary.bower@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.